Optimize value based care solutions and improve affordability with real-world evidence

Aetion provides a scalable way to assess the effectiveness, impact, and value of clinical programs and medications. Aetion Evidence Platform® (AEP), our software platform, ensures transparency, reproducibility, and credibility of results using scientifically validated workflows.

Learn more

Drive critical decisions with RWE.

For payers and at-risk providers

Perform clinical program evaluation that demonstrates ROI and informs resource allocation; enable controlled data access for life sciences collaborations

For life sciences

Generate RWE in payer-specific populations that support access initiatives and improve patient outcomes

For digital health

Demonstrate the clinical and financial value of your care model to support payer access and reimbursement

For outcomes research groups

Increase capacity to support research opportunities with our leading analytics platform

Aetion empowers organizations to understand true drivers of health outcomes through rigorous scientific methods, enabling investment in high value interventions and ultimately changing the trajectory of illness for patients.

— Bill Guptail

SVP of Value-Based Solutions, Aetion

Generate decision-grade evidence with Aetion.

AEP is scientifically validated software that analyzes data from the real world to produce transparent and rapid answers—on safety, effectiveness, and value.

Learn how we can help

Our impact

How real-world evidence supports outcomes-based care and contracting: A conversation with Dr. Saira Jan, Horizon BCBSNJ

ICER to use Aetion observational RWE to update value assessment of treatments for hereditary angioedema

Patient voice in RWE: Generating evidence that will impact payer and HTA decision-making

Empagliflozin and the risk of heart failure hospitalization in routine clinical care: A first analysis from the EMPRISE study

Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study

Cognito Therapeutics and Aetion announce partnership to use artificial intelligence to identify rapidly progressing forms of mild cognitive impairment and Alzheimer’s disease